Abstract Details

Title STARS: A Phase 2 Adult Angelman Syndrome Clinical Trial: Randomized, Double-blind, Safety and Efficacy Study of Gaboxadol

Topic Child Neurology and Developmental Neurology

Presentation(s) P3 - (-)

Poster/Presentation
Number 302

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Cesar Ochoa-Lubinoff PRESENTER	Cesar Ochoa-Lubinoff has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ovid Therapeutics Inc.
	No disclosure on file
Joseph Grieco, PhD (Ovid Therapeutics)	No disclosure on file
Jeannie Visootsak	No disclosure on file
	No disclosure on file
Alexander Kolevzon	Alexander Kolevzon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ovid Therapeutics. Alexander Kolevzon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Alexander Kolevzon has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ovid Therapeutics. Alexander Kolevzon has received stock or an ownership interest from Ovid Therapeutics. The institution of Alexander Kolevzon has received research support from AMO Pharma. Alexander Kolevzon has received publishing royalties from a publication relating to health care.
Ronald L. Thibert, DO	Dr. Thibert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ovid Pharmaceuticals.
	No disclosure on file

��ɫ��